S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

IMRX Immuneering Corporation

1.94

0.00 (0.00%)

Jan 31 2025 - Closed

Delayed by 15 minutes

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Immuneering Charts.

Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Immuneering Charts.

Immuneering Corporation News

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 17 January 2025 (2 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Monday 13 January 2025 (3 weeks ago) • Edgar (US Regulatory)

Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
Monday 13 January 2025 (3 weeks ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 7 January 2025 (4 weeks ago) • Edgar (US Regulatory)

Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms
Tuesday 7 January 2025 (4 weeks ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 2 January 2025 (4 weeks ago) • Edgar (US Regulatory)

Immuneering Launches Pancreatic Cancer Advisory Board
Thursday 19 December 2024 (1 month ago) • GlobeNewswire Inc.

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
Tuesday 17 December 2024 (2 months ago) • GlobeNewswire Inc.

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
Thursday 12 December 2024 (2 months ago) • GlobeNewswire Inc.

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
Wednesday 27 November 2024 (2 months ago) • GlobeNewswire Inc.

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
Wednesday 13 November 2024 (3 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Wednesday 13 November 2024 (3 months ago) • Edgar (US Regulatory)

More Immuneering Corporation News Articles

UAV Corpoation (PK)

Elite Pharmaceuticals (QB)

Valiant Eagle (PK)

Rennova Health (CE)

Northwest Biotherapeutics (QB)

GBT Technologies (PK)

Asia Broadband (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions